Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

upload.jpg

Race Oncology (ASX: RAC) CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year.

Dr Tillett affirms that Q3 results showed a healthy cash position for the company, thanks to the Research & Development Tax Incentive from the Australian Taxation Office, as well as the strong support of Race shareholders shown through the Bonus Options offer.
 
On the clinical side, Dr Tillett explains that the successful development of the RC220 bisantrene formulation sets the company up for commercialising its lead drug asset.

Stay up to date via Race's interactive investor hub, and make sure to submit any questions you have via the 'Ask a question button'.

Race in ausbiz: CEO Dr Daniel Tillett discusses clinical updates and financial position